Ipsen Group Overview
Update this profile
Share Price
$91.37
(As of Thursday Closing)
Ipsen Group General Information
Description
Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, endocrinology, neurosciences, and primary care. Ipsen maintains two segments: Specialty care and Consumer Healthcare. The company derives most of its sales from the specialty care segment, with a vast majority of sales being generated in Western European countries. Ipsen's research and development strategy focus on peptides and toxins. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Contact Information
Want to dig into this profile?
We’ll help you find what you need
Learn more
Ipsen Group Stock Performance
(As of Thursday Closing)
Stock Price
Previous Close
52 wk Range
Market Cap
Shares
Average Volume
EPS
$91.37
$89.84
$84.37 - $131.96
$7.54B
82.5M
112K
$9.25
Ipsen Group Financials Summary
In Thousands, USD
TTM
31-Dec-2021
FY 2021
31-Dec-2021
FY 2020
31-Dec-2020
FY 2019
31-Dec-2019
EV
7,634,773
7,634,773
7,469,472
8,328,283
Revenue
3,545,832
3,545,832
3,061,920
3,014,329
EBITDA
1,267,661
1,267,661
903,153
186,835
Net Income
764,474
764,474
624,672
(56,756)
Total Assets
5,668,803
5,668,803
5,304,847
4,824,469
Total Debt
784,742
784,742
1,071,055
1,134,958
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Ipsen Group Valuation & Funding
Deal Type
Date
Amount
Valuation/ EBITDA
Post-Val
Status
Debt
This information is available in the PitchBook Platform. To explore Ipsen Group‘s full profile, request access.
Request a free trial
Ipsen Group Comparisons
Description
Primary Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, e
Pharmaceuticals
Boulogne Billancourt, France
5,744
As of 2021
00000
00000000000
00000
tur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad m
00000 0000000000 00000000
Paris, France
00000
As of 0000
000000000000
tetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
000000000000000
Basel, Switzerland
000000
As of 0000
000000000000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trial
Ipsen Group Competitors (10)
Company Name
Financing Status
Location
Employees
Total Raised
Last Financing Date/Type
Last Financing Amount
Sanofi
Corporation
Paris, France
00000
000000000000
00000000
Corporation
Basel, Switzerland
000000
000000000000
000000 00000000000
Corporation
Parma, Italy
0000
000000000000000
Corporation
Brentford, United Kingdom
00000
000000000
000000000
Private Equity-Backed
Milan, Italy
0000
000000000000
You’re viewing 5 of 10 competitors. Get the full list »
Ipsen Group Patents
241
Total Documents
Applications and Grants
000
Total Patents
Families
13
Granted
11
Pending
000
Expiring
in next 12 mo
Ipsen Group Recent Patent Activity
Publication ID
Patent Title
Status
First Filing Date
Technology (CPC)
Citations
US-20200383894-A1
Treatment of moderate to very severe glabellar lines and lateral canthal lines
Pending
07-Jun-2019
00000000000
GB-201907016-D0
Screening method to determine suitability for participation in a clinical trial
Ceased
17-May-2019
00000000000
EP-3911742-A1
Sortase-labelled clostridium neurotoxins
Pending
16-Jan-2019
00000000
EP-3890772-A1
Treatment of symptoms of traumatic brain injury
Pending
05-Dec-2018
00000000000
EP-3888097-A1
Dosing calculator for spasticity
Pending
27-Nov-2018
G16H20/10
To view Ipsen Group’s complete patent history, request access »
Ipsen Group Executive Team (27)
Update this profile
Name
Title
Board Seat
Contact Info
David Loew
Chief Executive Officer & Board Member
Aymeric Le Chatelier
Executive Vice President & Group Chief Financial Officer
Dominique Laymand
Executive Vice-President & Chief Ethics and Compliance Officer
Philippe Lopes-Fernandes
Chief Business Officer & Executive Vice President
Francois Garnier
Executive Vice President, General Counsel and Chief Business Ethics Officer
You’re viewing 5 of 27 executive team members. Get the full list »
Ipsen Group Signals
Growth Rate
0.80%
Weekly Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial
Ipsen Group
Investments & Acquisitions (27)
Company Name
Deal Date
Deal Type
Deal Size
Industry
Lead Partner
0000000
27-Jun-2022
0000000000
00000
Drug Discovery
00000 000
0000 00000000
18-Nov-2021
00000 0000
0000
Drug Discovery
00000000
0000000
01-Jan-2021
00000 0000
Drug Discovery
0000000
15-Jun-2020
0000 00000
00.000
Enterprise Systems (Healthcare)
Clementia Pharmaceuticals
18-Apr-2019
Merger/Acquisition
00.000
Biotechnology
00000 000
You’re viewing 5 of 27 investments and acquisitions. Get the full list »
Ipsen Group Exits (7)
Company Name
Exit Date
Exit Type
Exit Size
Status
Buyers
000000 00000000000
16-Feb-2017
000000000
0000
Completed
00000 000000000000
13-Aug-2015
00000 00000 00
0000
Completed
000000 00000000000
13-Aug-2015
00000 00000 00
0000
Completed
000000 00000000000
29-Jul-2013
00000 00000 00
0000
Completed
Inserm Transfert
12-Jan-2012
Later Stage VC
000.00
Completed
You’re viewing 5 of 7 exits. Get the full list »